Kyverna Therapeutics (KYTX) Operating Leases (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Operating Leases data on file, last reported at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 112.13% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (up 112.13% YoY), and the FY2025 full-year result was $320000.0, down 92.31% from the prior year.
• Operating Leases for Q1 2026 stood at $7.0 million, up from $320000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $7.0 million in Q1 2026 and bottomed at $320000.0 in Q4 2025.
• The 4-year median for Operating Leases is $4.6 million (2024), against an average of $4.1 million.
• The widest annual swing landed in 2025, when Operating Leases sank 92.31%; it then jumped 112.13% in 2026.
• A 4-year view of Operating Leases shows it stood at $5.2 million in 2023, then declined by 20.58% to $4.2 million in 2024, then tumbled by 92.31% to $320000.0 in 2025, then surged by 2074.38% to $7.0 million in 2026.
• The last three Operating Leases figures came in at $7.0 million (Q1 2026), $320000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison